Alnylam Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Alnylam Pharmaceuticals, Inc.‘s stocks are currently a part of 417 hedge funds’ portfolios, which represents 94.77% of the total amount of its stocks outstanding. This makes up a total of 112.25M shares of Alnylam Pharmaceuticals, Inc.. Compared to the previous quarter, the number grew by 0.70% or 781.37K shares more. As for the holding position changes, 35.25% (147) of current hedge fund investors increased the number of shares held, 33.81% (141) of current holders sold a part of the shares held, and 14.15% (59) closed the holdings completely. 64 hedge funds are new holders of Alnylam Pharmaceuticals, Inc. stock in Q1 2022, it is 15.35% of total holders.
Hedge funds holding Alnylam Pharmaceuticals (Q2 2017 – Q1 2022)
| Q2 2017 | 220 |
|---|---|
| Q3 2017 | 229 |
| Q4 2017 | 274 |
| Q1 2018 | 284 |
| Q2 2018 | 302 |
| Q3 2018 | 297 |
| Q4 2018 | 275 |
| Q1 2019 | 282 |
| Q2 2019 | 282 |
| Q3 2019 | 274 |
| Q4 2019 | 305 |
| Q1 2020 | 318 |
| Q2 2020 | 362 |
| Q3 2020 | 343 |
| Q4 2020 | 361 |
| Q1 2021 | 376 |
| Q2 2021 | 388 |
| Q3 2021 | 391 |
| Q4 2021 | 416 |
| Q1 2022 | 417 |
Hedge funds changes in Alnylam Pharmaceuticals positions (Q2 2017 – Q1 2022)
| Q2 2017 | 51 | 76 | 61 | 23 | 9 |
|---|---|---|---|---|---|
| Q3 2017 | 44 | 69 | 84 | 32 | 0 |
| Q4 2017 | 75 | 100 | 63 | 28 | 8 |
| Q1 2018 | 47 | 111 | 83 | 33 | 10 |
| Q2 2018 | 56 | 123 | 78 | 38 | 7 |
| Q3 2018 | 36 | 112 | 92 | 40 | 17 |
| Q4 2018 | 29 | 107 | 99 | 49 | -9 |
| Q1 2019 | 36 | 107 | 87 | 30 | 22 |
| Q2 2019 | 40 | 117 | 72 | 37 | 16 |
| Q3 2019 | 36 | 104 | 78 | 43 | 13 |
| Q4 2019 | 68 | 96 | 98 | 29 | 14 |
| Q1 2020 | 51 | 119 | 93 | 33 | 22 |
| Q2 2020 | 73 | 136 | 106 | 27 | 20 |
| Q3 2020 | 28 | 123 | 127 | 47 | 18 |
| Q4 2020 | 55 | 124 | 121 | 36 | 25 |
| Q1 2021 | 53 | 145 | 114 | 34 | 30 |
| Q2 2021 | 55 | 138 | 126 | 41 | 28 |
| Q3 2021 | 48 | 152 | 117 | 41 | 33 |
| Q4 2021 | 71 | 154 | 126 | 40 | 25 |
| Q1 2022 | 64 | 147 | 141 | 59 | 6 |
Hedge funds changes in Alnylam Pharmaceuticals stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 90,205,000 | 81,486,000 |
|---|---|---|
| Q3 2017 | 392,430,000 | 323,195,000 |
| Q4 2017 | 164,607,000 | 143,973,000 |
| Q1 2018 | 108,562,000 | 105,062,000 |
| Q2 2018 | 106,116,000 | 56,372,000 |
| Q3 2018 | 2,138,664,000 | 105,410,000 |
| Q4 2018 | 123,488,000 | 51,882,000 |
| Q1 2019 | 82,371,000 | 52,460,000 |
| Q2 2019 | 74,487,000 | 55,520,000 |
| Q3 2019 | 113,021,000 | 79,477,000 |
| Q4 2019 | 154,667,000 | 139,407,000 |
| Q1 2020 | 153,850,000 | 133,756,000 |
| Q2 2020 | 153,556,000 | 120,043,000 |
| Q3 2020 | 136,279,000 | 130,805,000 |
| Q4 2020 | 133,384,000 | 122,748,000 |
| Q1 2021 | 83,873,000 | 54,407,000 |
| Q2 2021 | 274,443,000 | 257,553,000 |
| Q3 2021 | 274,854,000 | 143,209,000 |
| Q4 2021 | 251,419,000 | 189,278,000 |
| Q1 2022 | 143,264,000 | 198,885,000 |